Osphos combats excessive bone resorption. The Bisphosphonate Clodronic acid helps to restore the balance between resorption and remodelling in diseased bone. It binds to hydroxyapatite crystals on the navicular bone which are taken in by the osteoclast during bone resorption. This inhibits osteoclast activity by preventing them from adhering to the bone surface and inducing osteoclast cell death and helps to reduce mineral loss.
Osphos is administered by simple intramuscular injection and should be evenly spread over 2 to 3 injection sites.